The Dream of HIV Vaccines May Finally Be Coming True
1 min read
Summary
Two separate studies have produced encouraging results in the quest for an HIV vaccine, using mRNA technology similar to that deployed against COVID.
In one study, mRNA molecules encoding the protein stem of HIV were successfully produced in cells in a way that alerted the body’s immune system, subsequently producing HIV-blocking antibodies in up to 80% of trial participants.
The other study, which also produced promising results in monkeys and rabbits, saw an 80% success rate among human trial participants in producing antibodies that could block HIV, with a relatively low 6.5% incidence of noteworthy side effects.
While the results are promising, experts have warned that further research is needed before firm conclusions can be drawn.
